Topoisomerase II inhibitor-related acute myeloid leukaemia.
Pui
C H
CH
St Jude Children's Research Hospital and the University of Tennessee, Memphis 38105, USA.
Relling
M V
MV
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002880:Chromosomes, Human, Pair 11; D004268:DNA-Binding Proteins / Q000235:genetics; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004357:Drug Synergism; D015321:Gene Rearrangement / Q000235:genetics; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced* / Q000235:genetics / Q000628:therapy; D051788:Myeloid-Lymphoid Leukemia Protein; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D011519:Proto-Oncogenes; D012074:Remission Induction; D012307:Risk Factors; D059005:Topoisomerase II Inhibitors; D014157:Transcription Factors; D014178:Translocation, Genetic / Q000235:genetics
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; C497422:KMT2A protein, human; D059005:Topoisomerase II Inhibitors; D014157:Transcription Factors; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase